5-MeO-DMT produces one of the shortest and most intense psychedelic experiences in clinical research. The acute dosing window is typically 15–30 minutes, but the responsibility around it—rigorous screening, real-time monitoring, same-day integration prompts, and longitudinal follow-up—extends across weeks. Ignite Synergy is the software backbone for that protocol.
5-MeO-DMT-aware workflows for clinical and research programs
- Pre-screening for cardiovascular risk, psychotic spectrum history, and medication interactions
- Tight pre-session preparation and consent capture
- Real-time vitals and adverse event logging during 15–30 minute dosing windows
- Dyad/sitter coordination and safety escalation pathways
- Same-day integration prompts to capture insight before it fades
- Multi-week integration program with journaling, intention revisits, and outcomes tracking
Why short sessions still need extended infrastructure
The 5-MeO-DMT experience is short in clock time but disproportionately large in psychological impact. Patients often describe "ego dissolution" experiences that require careful integration to translate into lasting change. Our integration workflow and adherence follow-through modules ensure the days and weeks after dosing are structured—because for 5-MeO-DMT, that's where most of the therapeutic work happens.
Safety, screening, and adverse event tracking
5-MeO-DMT can produce rapid increases in heart rate and blood pressure, vomiting, and intense psychological content including ego dissolution and challenging experiences. Our pre-screening workflow flags risk patterns early. Our adverse event tracking module captures cardiovascular events, behavioral concerns, and prolonged distress in a structured, reportable format suitable for clinical trials and regulator submissions.
Hubs: For clinics · Features · AI pre-screening · Integration workflow · Contact
Learn more about 5-MeO-DMT and psychedelic care
- FAQ: Psychedelics & mental health research — what the evidence does and does not say.
- Neuroplasticity & intention setting — why integration is where the work happens.
- Beyond the breakthrough — infrastructure for psychedelic care at scale.
Trusted external resources
Independent research centers, directories, and clinical programs—provided for reference (Ignite Synergy is not affiliated unless explicitly stated).
- GH Research — Clinical-stage developer of inhaled 5-MeO-DMT (GH001) for treatment-resistant depression.
- Beckley Psytech — Clinical research on short-duration psychedelic therapeutics, including intranasal 5-MeO-DMT (BPL-003).
- MAPS (Multidisciplinary Association for Psychedelic Studies) — Education and research across psychedelic-assisted therapy.
Note: 5-MeO-DMT is a Schedule I controlled substance under U.S. federal law outside of narrow research and religious-exemption contexts. Ignite Synergy is software infrastructure for legally operating programs—clinical research, religious-exempt practices, and clinics in jurisdictions where 5-MeO-DMT therapy is authorized.